Tetherex is focused on development of anti-PSGL-1 antibodies for the treatment of inflammatory and thrombotic diseases.
Selexys Pharmaceuticals? pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutics for inflammatory and thrombotic diseases and positioned Selexys with strong scientific underpinnings.
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.?